Collins C Iwuji1, Nuala McGrath2, Tulio de Oliveira3, Kholoud Porter4, Deenan Pillay5, Martin Fisher6, Melanie Newport7, Marie-Louise Newell8. 1. Africa Centre for Health and Population Studies, University of KwaZulu Natal, South Africa; Research Department of Infection and Population Health, University College London, UK. 2. Africa Centre for Health and Population Studies, University of KwaZulu Natal, South Africa; Academic Unit of Primary Care and Population Sciences, and Department of Social statistics and Demography, University of Southampton, UK. 3. Africa Centre for Health and Population Studies, University of KwaZulu Natal, South Africa. 4. MRC Clinical Trials Unit at UCL, London, UK. 5. Africa Centre for Health and Population Studies, University of KwaZulu Natal, South Africa; Research Department of Infection and Immunity, University College London, UK. 6. Division of Medicine, Brighton and Sussex Medical School, UK. 7. Department of Infectious Diseases and Global Health, Brighton and Sussex Medical School, UK. 8. Faculty of Medicine and Faculty of Social and Human Sciences, University of Southampton, UK.
Abstract
INTRODUCTION: Remarkable strides have been made in controlling the HIV epidemic, although not enough to achieve epidemic control. More recently, interest in biomedical HIV control approaches has increased, but substantial challenges with the HIV cascade of care hinder successful implementation. We summarise all available HIV prevention methods and make recommendations on how to address current challenges. DISCUSSION: In the early days of the epidemic, behavioural approaches to control the HIV dominated, and the few available evidence-based interventions demonstrated to reduce HIV transmission were applied independently from one another. More recently, it has become clear that combination prevention strategies targeted to high transmission geographies and people at most risk of infections are required to achieve epidemic control. Biomedical strategies such as male medical circumcision and antiretroviral therapy for treatment in HIV-positive individuals and as pre-exposure prophylaxis in HIV-negative individuals provide immense promise for the future of HIV control. In resource-rich settings, the threat of HIV treatment optimism resulting in increased sexual risk taking has been observed and there are concerns that as ART roll-out matures in resource-poor settings and the benefits of ART become clearly visible, behavioural disinhibition may also become a challenge in those settings. Unfortunately, an efficacious vaccine, a strategy which could potentially halt the HIV epidemic, remains elusive. CONCLUSION: Combination HIV prevention offers a logical approach to HIV control, although what and how the available options should be combined is contextual. Therefore, knowledge of the local or national drivers of HIV infection is paramount. Problems with the HIV care continuum remain of concern, hindering progress towards the UNAIDS target of 90-90-90 by 2020. Research is needed on combination interventions that address all the steps of the cascade as the steps are not independent of each other. Until these issues are addressed, HIV elimination may remain an unattainable goal.
INTRODUCTION: Remarkable strides have been made in controlling the HIV epidemic, although not enough to achieve epidemic control. More recently, interest in biomedical HIV control approaches has increased, but substantial challenges with the HIV cascade of care hinder successful implementation. We summarise all available HIV prevention methods and make recommendations on how to address current challenges. DISCUSSION: In the early days of the epidemic, behavioural approaches to control the HIV dominated, and the few available evidence-based interventions demonstrated to reduce HIV transmission were applied independently from one another. More recently, it has become clear that combination prevention strategies targeted to high transmission geographies and people at most risk of infections are required to achieve epidemic control. Biomedical strategies such as male medical circumcision and antiretroviral therapy for treatment in HIV-positive individuals and as pre-exposure prophylaxis in HIV-negative individuals provide immense promise for the future of HIV control. In resource-rich settings, the threat of HIV treatment optimism resulting in increased sexual risk taking has been observed and there are concerns that as ART roll-out matures in resource-poor settings and the benefits of ART become clearly visible, behavioural disinhibition may also become a challenge in those settings. Unfortunately, an efficacious vaccine, a strategy which could potentially halt the HIV epidemic, remains elusive. CONCLUSION: Combination HIV prevention offers a logical approach to HIV control, although what and how the available options should be combined is contextual. Therefore, knowledge of the local or national drivers of HIV infection is paramount. Problems with the HIV care continuum remain of concern, hindering progress towards the UNAIDS target of 90-90-90 by 2020. Research is needed on combination interventions that address all the steps of the cascade as the steps are not independent of each other. Until these issues are addressed, HIV elimination may remain an unattainable goal.
Entities:
Keywords:
Antiretroviral therapy; Combination HIV prevention; HIV; HIV cascade; HIV vaccines; Post-exposure prophylaxis; Pre-exposure prophylaxis
Authors: Peter Piot; Salim S Abdool Karim; Robert Hecht; Helena Legido-Quigley; Kent Buse; John Stover; Stephen Resch; Theresa Ryckman; Sigrun Møgedal; Mark Dybul; Eric Goosby; Charlotte Watts; Nduku Kilonzo; Joanne McManus; Michel Sidibé Journal: Lancet Date: 2015-06-24 Impact factor: 79.321
Authors: Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Kishor Mandaliya; Francesca Conradie; Mariette E Botes; Maureen Wellington; Akin Osibogun; Kim C E Sigaloff; Immaculate Nankya; Rob Schuurman; Ferdinand W Wit; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit Journal: Lancet Infect Dis Date: 2011-07-27 Impact factor: 25.071
Authors: Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya Journal: J Infect Dis Date: 2006-11-03 Impact factor: 5.226
Authors: Claire L Townsend; Mario Cortina-Borja; Catherine S Peckham; Annemiek de Ruiter; Hermione Lyall; Pat A Tookey Journal: AIDS Date: 2008-05-11 Impact factor: 4.177
Authors: Maurice Musheke; Harriet Ntalasha; Sara Gari; Oran McKenzie; Virginia Bond; Adriane Martin-Hilber; Sonja Merten Journal: BMC Public Health Date: 2013-03-11 Impact factor: 3.295
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Allahna L Esber; Peter Coakley; Julie A Ake; Emmanuel Bahemana; Yakubu Adamu; Francis Kiweewa; Jonah Maswai; John Owuoth; Merlin L Robb; Christina S Polyak; Trevor A Crowell Journal: J Int AIDS Soc Date: 2020-02 Impact factor: 5.396